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Abstract: Seizures are common in patients with high-grade gliomas (30–60%) and approximately 
15–30% of glioblastoma (GB) patients develop drug-resistant epilepsy. Reliable animal models are 
needed to develop adequate treatments for glioma-related epilepsy. Therefore, fifteen rats were 
inoculated with F98 GB cells (GB group) and four rats with vehicle only (control group) in the right 
entorhinal cortex. MRI was performed to visualize tumor presence. A subset of seven GB and two 
control rats were implanted with recording electrodes to determine the occurrence of epileptic 
seizures with video-EEG recording over multiple days. In a subset of rats, tumor size and expression 
of tumor markers were investigated with histology or mRNA in situ hybridization. Tumors were 
visible on MRI six days post-inoculation. Time-dependent changes in tumor morphology and size 
were visible on MRI. Epileptic seizures were detected in all GB rats monitored with video-EEG. 
Twenty-one days after inoculation, rats were euthanized based on signs of discomfort and pain. 
This study describes, for the first time, reproducible tumor growth and spontaneous seizures upon 
inoculation of F98 cells in the rat entorhinal cortex. The development of this new model of GB-
related epilepsy may be valuable to design new therapies against tumor growth and associated 
epileptic seizures. 
Keywords: glioma; seizures; high-grade glioma rat model; glioma-related epilepsy; video-EEG 
monitoring 
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1. Introduction 
Glial tumors or gliomas represent 80% of all malignant brain tumors [1,2]. According to the 
World Health Organization (WHO) classification system, gliomas can be histologically classified as 
low-grade gliomas (LGG; ±15% of all gliomas) or high-grade gliomas (HGG; ±85% of all gliomas). 
Eighty percent of HGG are grade IV gliomas, also termed glioblastoma (GB), representing the most 
common and malignant brain tumor and carrying a poor prognosis, with medium survival rates of 
12–17 months after diagnosis [3–7]. 
Seizures represent a common symptom in GB and occur in 30–60% of patients with GB [3,8]. 
Brain tumor-related seizures typically have a focal onset and can be associated with alteration of 
consciousness and secondary generalization [3]. Up to 30% of patients with GB suffer from drug-
resistant epilepsy (DRE), resulting in significant morbidity and negative impact on quality of life [3,9–
11]. 
Investigating the mechanisms of GB development in animal models is essential to develop 
effective treatments. Animal models provide the opportunity to study the characteristics of tumor 
development and the occurrence of GB-related seizures as well as the pathogenic processes 
underlying epileptogenesis. This may lead to the identification of new targets for treatment 
development against GB invasion, GB-related seizures, and ultimately, help to improve quality of life 
in patients with GB. 
Different studies investigated the mechanisms of epileptogenesis in brain tumors, but these 
mechanisms remain poorly understood and are likely to be multifactorial, involving both host and 
tumor factors [12]. In vitro analysis on brain slices in rat and mouse models of GB showed neuronal 
hyperexcitability in peritumoral regions (1–2 mm from main tumor mass), which triggers 
epileptiform activity [13,14]. This phenomenon was also observed in a clinical setting, where 
magnetoencephalography (MEG) demonstrated abnormal low frequency activity in the peritumoral 
area in 13 out of 20 patients with tumor-related epilepsy [15]. Pathophysiological mechanisms that 
contribute to glioma-associated neuronal hyperexcitability include ischemia, neuronal network 
disruption/reorganization, altered gap junction coupling, abnormal ion and neurotransmitter levels, 
neural plasticity, and pronounced gliosis with chronic inflammatory changes [9,16–20]. Recently, it 
has been suggested that bidirectional interactions between neurons and glioma play an important 
role in glioma progression: neuronal activity increases glioma growth and gliomas increase neuronal 
activity [18,19]. 
Although many rodent glioma models have been described [21], these models were not designed 
to study the evolution of GB over time in relation to the occurrence of epilepsy and certainly not with 
personalized video-EEG monitoring. In this paper, we describe the progression and histopathological 
properties as well as the occurrence of seizures and the development of epilepsy in the syngeneic 
Fischer/F98 rat model of GB. 
2. Results 
2.1. Tumor Growth 
Fifteen male F344/IcoCrl rats were inoculated with 20,000 F98 cells in 5 µL phosphate-buffered 
saline (PBS) in the right entorhinal cortex (GB1–15). In four control animals (C1–4), 5 µL of PBS was 
injected at the same location. We refer to the day of inoculation as post-inoculation day 0 (PID0). MRI 
was performed in GB rats at different time points after inoculating F98 glioma cells in the entorhinal 
cortex. It has to be noted that MRI is performed in different rats at the different time points, except at 
PID3 and PID10, and at PID14 and PID19 (Table 1, M). At all time points, except at PID3, presence of 
a tumor was demonstrated with MRI. Representative T2 images at different time points post-
inoculation are shown in Figure 1A. MRI tumor volumes in GB rats at different time points post-
inoculation can be found in Figure 1B. The size of the tumor increased with time post-inoculation. In 
all four GB rats scanned on PID6 (GB6–9), a hyperintense T2 signal was observed at the inoculation 
site, indicating the presence of a tumor (median 4.5 mm3, range 1.4–6.7 mm3). On PID8, a larger 
homogeneous hyperintense zone (median 8.8 mm3, range 4.2–8.9 mm3) was observed at the 
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inoculation site in all three scanned GB rats (GB10–12). On PID10, heterogeneous tumors (median 
40.6 mm3, range 27.5–62.1 mm3) with three distinct tumor zones could be identified in all five scanned 
GB rats (GB1–5) on T2 images: (1) a central zone of hyperintense signal; (2) a rim of a relatively 
hypointense signal; and (3) an outer rim of less intense signal (Figure 1A, MRI slice 2 at PID10). In 
the three GB rats scanned on PID14 and PID19 (GB13–15), tumors were large (median 86.9 mm3, range 
71.2–162.6 mm3) and started to deform the brain on PID14 and became massive (median 304.8 mm3, 
range 234.8–460.6 mm3), pushing on the left hemisphere and brainstem on PID19. MRI was only 
performed in two control animals on PID8 (C3–4). In these animals, no abnormalities were observed. 
Table 1. Overview of timing of the different procedures per animal. MRI (M) was performed in 
different animals at different time points. After confirmation of tumor growth, electrodes were 
implanted (E) in a subset of animals. GB1 died during electrode implantation (Ϯ). GB3 was left out for 
analysis due to bad EEG signals (shaded). Tissue from monitored animals was collected on PID21 for 
histological analysis (H). Tissue from GB10–12 and C3–4 was collected the day after MRI for 
RNAscope analysis (R). 
M—MRI scan; E—EEG electrode implantation; R—RNAscope analysis; H—histological analysis; 
H(●)—no histological analysis due to problems with tissue processing. 
 Post-Inoculation Day (PID) 
 
PID PID PID PID PID PID PID PID PID PID PID PID PID PID PID PID PID PID PID 
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
GB1 M       M Ϯ           
GB2 M       M E Video-EEG monitoring H(●) 
GB3 M       M E Video-EEG monitoring H(●) 
GB4 M       M E Video-EEG monitoring H(●) 
GB5 M       M  E Video-EEG monitoring H(●) 
GB6    M E Video-EEG monitoring H 
GB7    M E Video-EEG monitoring H 
GB8    M  E Video-EEG monitoring H 
GB9    M  E Video-EEG monitoring H 
GB10      M R             
GB11      M R             
GB12      M R             
GB13            M     M   
GB14            M     M   
GB15            M     M   
 
C1   E Video-EEG monitoring H 
C2   E Video-EEG monitoring H 
C3      M R             
C4      M R             
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Figure 1. Tumor evolution and deformation of the brain over time. (A) Deformation of the brain over 
time. This figure shows consecutive (MRI slice 1 to 4, posterior to anterior) T2 MRI images (slice 
thickness: 0.6 mm—interslice thickness: 1.2 mm) in a rat brain at different time points: PID6: 
Hyperintense T2 signal at inoculation site (GB9); PID10: three distinct tumor zones can be identified 
(GB5); PID14: large tumor starts to deform the brain (GB14); PID19: massive tumor deforms the brain, 
pushes on the brainstem, and causes a midline shift (GB14). T2 MRI images “MRI slice 2” are taken 
around the inoculation site, while T2 MRI images “MRI slice 4” are taken close to the electrodes 
implanted in the hippocampi. PID—post-inoculation day. * indicates that images of PID14 and PID19 
are obtained in the same GB animal (GB14). (B) Tumor volumes on MRI for different GB rats in 
function of time. In this graph, MRI tumor volumes for individual rats are shown for different points 
in time (days post-inoculation). Note that overlay of rats is present on PID6 (GB6–7 and GB8–9) and 
PID8 (GB11–12). Lines connect MRI tumor volumes of the same rats at different time points. 
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2.2. Seizures 
After confirmation of tumor growth on the MRI, recording electrodes were implanted in both 
hippocampi and in the ipsilateral parietal cortex in a subset of GB rats (GB1–9). Two out of four 
control rats (C1–2) were also implanted with electrodes. Time points of electrode implantation varied 
between PID5 and PID12 (Table 1, E). GB1 died during implantation surgery. In GB3, EEG recordings 
could not be interpreted due to bad signal quality. The remaining nine animals (seven GB rats and 
two control rats) were monitored continuously with video-EEG starting immediately after electrode 
implantation until euthanasia (Table 1). The number of seizures per day per rat, categorized per stage, 
is shown in Table 2. 
Seizures occurred in all monitored GB rats between PID8 and PID21 with a high interindividual 
variability in the number of seizures and day of occurrence. Overall, the number of seizures per GB 
rat did not increase over time nor the fraction of rats having seizures. No significant difference in 
seizure occurrence during the light phase (median 11, range 5–18) versus dark phase (median 4, range 
0–37) was found (Wilcoxon Signed Rank Test, p = 0.993). Median severity of seizures in GB rats was 
score 1 on the modified Racine Scale (range 1–5). GB rats had significantly more (Wilcoxon test, p = 
0.018) non-convulsive (median 10, range 6–31) than convulsive seizures (median 6, range 0–21). 
Median electrographic seizure duration in GB rats was 75.4 s (range 24–257 s). The electrographic 
duration of non-convulsive seizures (median 60.4 s, range 24–203.5 s) was significantly shorter 
(Mann–Whitney U Test, p = 0.004) compared to convulsive seizures (median 109.69 s, range 24.5–257 
s). In both monitored control rats, stage 5 seizures were observed, but these seizures were limited to 
day 1 and 2 after electrode implantation (PID6 and 7). These convulsive stage 5 seizures showed 
different EEG and behavioral characteristics than the majority of stage 5 seizures in GB rats, although 
GB rats implanted with electrodes on PID7–8 did show similar seizures shortly after electrode 
implantation. These specific type of stage 5 seizures (indicated with * in Table 2) were primary 
generalized, with simultaneous electrographic onset on all four EEG channels (Figure 2C) and rats 
showed immediate convulsive behavior at electrographic seizure onset and not the typical sequential 
evolution in behavior (initial freezing and head nodding followed by forelimb clonus and later on, 
hindlimb clonus and falling). Furthermore, these stage 5 seizures (median 47.5 s, range 24.5–85 s) 
were significant shorter (Mann–Whitney U Test, p < 0.001) in duration than other stage 5 seizures 
(median 132.7 s, range 58.5–257 s). 
In GB rats, a clear attenuation of the EEG signal amplitude with time post-inoculation was 
observed first in ipsilateral but finally also in the contralateral hippocampus. Electrographic seizures 
could still be clearly discriminated (Figure 2). 
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Table 2. Timeline with occurrence of seizures in individually monitored rats. Number of seizures per 
day and per stage during the entire video-EEG monitoring period in individual rats is indicated in 
the table. As rats were implanted with electrodes at different time points, days before electrode 
implantation—on which no video-EEG monitoring was performed—are shaded. Furthermore, 
fraction of rats with seizures per day (RWS) and total number of non-convulsive seizures (NCS) and 
convulsive seizures (CS) are indicated. Based on the Racine scale, stage 1 and 2 seizures with no clear 
motor component were classified as non-convulsive seizures and stage 3–5 seizures with a clear motor 
component were classified as convulsive seizures. Convulsive seizure stages are shaded in grey. 
Primary generalized seizures shortly after electrode implantations are marked with *. 
 Post-Inoculation Day (PID) 
Rat 
Severity 
(Racine 
Scale) 
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
GB2 
1            1    6  1  
2                    
3                    
4                    
5                    
GB4 
1            1    2 1 6  
2                    
3             3    1   
4                   1 
5                   1 
GB5 
1           1  5     2  
2                    
3                  2  
4                    
5                    
GB6 
1        1 3 5 18       2  
2           2         
3           1 6 5   1    
4              1  1    
5      2 *            2 2 
GB7 
1         17           
2               1  4 1  
3         3      1     
4         1      1  3   
5      5 * 1 *        1  1   
GB8 
1          1   1 3  1    
2                    
3                1    
4                    
5       2 *             
GB9 
1            5  6 2     
2                    
3              2      
4                2    
5               5     
Total GB 
RWS     0/2 2/4 2/4 1/4 2/6 2/7 2/7 4/7 4/7 3/7 2/7 5/7 2/7 5/7 2/7 
NCS/CS      0/7 0/3 1/0 
20/
4 
6/0 21/1 7/6 6/8 9/3 3/8 9/5 5/5 12/4 0/4 
C1 
1                    
2                    
3                    
4                    
5    3 *                
C2 
1                    
2                    
3                    
4                    
5    8 * 4 *               
Total control 
RWS   0/2 2/2 1/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 
NCS/CS    0/11 0/4               
Int. J. Mol. Sci. 2020, 21, 6999 7 of 19 
 
 
Figure 2. Examples of seizures on EEG. (A) representative spontaneous stage 1 seizure at PID15 in 
GB5. (B) representative spontaneous stage 1 seizure at PID20 in GB5. (C) representative spontaneous 
stage 5 seizure at PID6 in C1. Dashed lines indicate beginning and end of the seizures. The first 
channel represents EEG recorded from the ipsilateral dentate gyrus (DGi), the second channel EEG 
recorded from the ipsilateral CA1 (CA1i), the third channel EEG recorded from the contralateral 
dentate gyrus (DGc), and the fourth channel EEG recorded from the surface electrode at the tumor 
border (Cp). 
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2.3. Expression of Proliferative and Glial Markers in the Tumor and Its Microenvironment 
Histological characteristics of F98 GB tumors at PID21 included necrotic areas surrounded by 
tumor cells, marked hypercellularity, nuclear atypia, and infiltrative growth (Figure 3A–C). 
Immunohistochemical analysis confirmed the expression of astrocytic lineage markers (GFAP, 
vimentin) by the GB cells (Figure 3D–G). Vimentin and GFAP labeling are both dense at the tumor 
border, where these cells display a palisade arrangement in their cell processes (Figure 3E–F). 
However, there is high heterogeneity in GFAP expression throughout the tumor, ranging from 0 to 
100% GFAP+ cells per evaluated random high power field (of 40×-magnification), with a higher 
number of GFAP+ cells further away from the tumor core, whereas vimentin expression remains high 
(approximately 100%) in all tumor regions. In tumor tissue, 46 ± 3% (mean ± SD) of cells were Ki-67 
positive, confirming their mitotic state. Only 2 ± 2% (mean ± SD) of cells in the adjacent normal brain 
parenchyma were found to be Ki-67 positive (Figure 3H–J). 
 
Figure 3. Histological and immunohistochemical analysis. (A–C) Cresyl violet staining: (A) This 
overview picture shows a tumor-containing coronal slice stained with cresyl violet. Tumor tissue can 
be clearly identified on the right of the slice, appearing dark purple as opposed to less intense stained 
normal brain tissue. (B) Cresyl violet staining in tumor tissue, 20× magnification: This figure shows a 
necrotic spot surrounded by palisading tumor cells (N), as well as nuclear atypia and marked 
hypercellularity. (C) Cresyl violet staining at tumor border, 20× magnification: This figure shows the 
transition from tumor (T) to non-tumor (NT) tissue, including an infiltrative spot (I). (D–G) 
Expression of GFAP and vimentin: (D) DAPI staining: Tumor tissue contains more densely packed 
cells compared to neighboring non-tumor tissue, as demonstrated by DAPI positive nuclei. (E) GFAP 
staining: GFAP labeling is mainly found at tumor border and diffuse in tumor tissue. (F) Vimentin 
staining: Vimentin labeling is found at tumor border and diffuse in tumor tissue. (G) DAPI, vimentin, 
and GFAP overlay: Many double positive cells align at tumor border. (H–J) Expression of Ki-67: (H) 
DAPI staining. (I): Ki-67 staining. (J): DAPI and Ki-67 overlay: Ki-67 positive cells are seen in tumor 
tissue and infiltrative spots, whereas most cells in adjacent non-tumor tissue are Ki-67 negative. T—
tumor tissue; NT—non-tumor tissue; I—infiltrative spot; N—necrotic spot. 
RNA scope analysis at PID9 (Table 1, R) showed high levels of GFAP mRNA around the area of 
dense tumor cells in GB rats (Figure 4B). However, almost no GFAP mRNA was found in the tumor, 
whereas heterogeneous GFAP expression was observed inside the tumor by immunohistochemistry 
at PID21. When MRI images at PID8 (Figure 4A) were compared with RNAscope images at PID9, the 
hyperintense signal on the MRI (Figure 4C, aligned in red) extended beyond the area of dense tumor 
cells (Figure 4D, aligned in blue) and included a large part of a GFAP+ astrogliotic rim around the 
dense tumor core as well (Figure 4D, aligned in red). Hyperintense areas on MRI images were two to 
Int. J. Mol. Sci. 2020, 21, 6999 9 of 19 
 
three times larger than areas of dense tumor cells on RNAscope slices. These hyperintense areas were 
27 ± 5% (mean ± SD) smaller than the composite areas including the dense tumor cells and astrocytic 
rim on RNAscope slices (Table 3). GFAP mRNA levels were increased in control rats along the 
injection tract (Figure 4F). 
 
Figure 4. Expression of GFAP mRNA and comparison with MRI. (A) Representative T2 MRI image 
of a GB rat on PID8. A homogeneous hyperintense zone can be identified ipsilateral of the inoculation 
site. (B) Representative RNAscope image of the same GB rat on PID9. This image shows a large tumor 
(strong DAPI staining) surrounded by high level of GFAP mRNA expression. (C) Alignment of the 
hyperintense zone (red) and whole brain (yellow) on the T2 MRI image of a GB rat on PID8. Relative 
size of the hyperintense zone is calculated by dividing its area by the total area of the brain slice on 
MRI. (D) Alignment of tumor (blue) and tumor + rim of strong GFAP mRNA expression (red). 
Relative areas are calculated by dividing the blue and red area by the total area of the brain slice on 
the RNA scope image (yellow). (E) Representative T2 MRI image of a control rat (C4) on PID8. (F) 
Representative RNAscope image of C4 on PID9. The red arrow indicates the injection tract, in which 
there is an increase in GFAP mRNA expression. 
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Table 3. MRI vs. RNAscope. This table summarizes the different relative areas calculated on MRI and 
RNAscope images. We can see that hyperintense areas on MRI extend beyond strongly DAPI-stained 
areas on RNAscope, but are smaller than areas including a high level of GFAP mRNA on RNAscope. 
 MRI PID8 RNAscope PID9 
 Hyperintense Area (%) DAPI Area (%) DAPI + GFAP mRNA Area (%) 
GB10 5.05 1.64 6.37 
GB11 4.04 1.42 5.75 
GB12 6.09 2.78 8.63 
2.4. End-Stage Tumor Volumes 
Tumor volumes at PID21 of GB6, GB7, GB8, and GB9 were 243, 262, 151, and 145 mm3. These 
respective animals had a total number of 52, 40, 9, and 22 seizures. Based on this low number of 
animals, no clear link between total number of seizures and end-stage tumor volumes was seen. 
Tumor volumes (expressed as means ± SEM) evaluated on T2 MRI at PID19 (333 ± 66 mm3) 
tended to be larger (p = 0.229) than histological tumor volumes at PID21 (200 ± 30 mm3). 
3. Discussion 
This study characterizes tumor development at various time points using both structural 
imaging and histology following F98 GB inoculation in the entorhinal cortex. In addition, the study 
describes, for the first time, the epileptic phenotype associated with tumor evolution in this model. 
Tumor inoculation in the right entorhinal cortex was successful in all animals as all animals 
developed tumor lesions. On day 6 post-inoculation, GB tumors could be demonstrated with 
preclinical MRI at the site of inoculation. Tumor development was very similar to that of human GB 
[6]. Lesions in our model progressed in size over time and invaded the brain. Necrotic zones in GB 
tumors were detected in animals on MRI at PID10, 14, and 19. At PID14, MRI shows a clear shift 
forward of the right hippocampus as a consequence of the presence of the space-occupying lesion. At 
PID19, MRI showed massive tumors causing a real deformation of the brain, including the left-brain 
hemisphere. This deformation of the brain could possibly explain the attenuation of the EEG signal 
resulting from loss of input from the entorhinal cortex. Ultimately, tumor evolution led to the decision 
of euthanasia of the animals based on signs of serious discomfort predicting nearing mortality. The 
trend towards larger tumor volumes calculated from MRI images compared to tumor volumes 
calculated from histological slices was expected as T2 MRI visualizes the tumor itself, as well as the 
infiltrative border of the tumor and brain edema [22]. RNAscope results showed that GB tumors are 
surrounded by reactive gliosis reflected by the high level of GFAP mRNA surrounding the dense 
tumor core. Comparison with MRI images of PID8 confirmed that this reactive gliosis was also 
hyperintense on T2 MRI. Immunohistochemistry for GFAP and vimentin at PID21 confirmed the glial 
origin of the developed tumors. Vimentin was profuse in tumor tissue and at the tumor border, 
whereas GFAP staining was only profuse at the tumor border and more heterogeneously expressed 
throughout the tumor. At PID9, high levels of GFAP mRNA were also detected in tissue surrounding 
the tumor, but not in tumor tissue. Vimentin expression is an early event in normal glial 
differentiation, while GFAP only appears in later stages [23,24]. Therefore, a possible explanation is 
that the majority of tumor cells in these GB tumors were neoplastic astrocytes in a dedifferentiated 
state. Dense GFAP labeling in the brain parenchyma surrounding the tumor reflects the presence of 
reactive astrocytes [24]. Tumor-associated astrocytes can be activated by neighboring glioma cells 
and reactive astrocytes promote proliferation, invasion, and treatment resistance of GB via a complex 
interaction (involving gap junctions, ion channels and transporters, chemokines, and cytokines) with 
the tumor microenvironment [25]. Many cells in the GB tumor tissue stained positive for the 
proliferative marker Ki-67 and thus, actively divided [26], confirming the high grade of invasiveness. 
We found a Ki-67 index of 47.30%, which is very comparable to the proliferative index of 46% 
reported by Belloli et al. [27] in a similar F98 GB rat model. 
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All GB rats demonstrated seizures throughout the video-EEG monitoring period (PID8–21), with 
the majority of seizures being non-convulsive. Primary generalized convulsive seizures occurred in 
SHAM-inoculated control rats (implanted with electrodes on PID5) and in GB rats implanted with 
electrodes on PID7 and PID8 but not on PID11 and PID12. The short interval between two consecutive 
brain surgeries (inoculation—electrode implantation) might have stimulated the occurrence of these 
post-implantation seizures. Acute inflammatory response due to the injection procedure may have 
had a negative influence on the outcome of the electrode implantation surgery. Our RNAscope 
analysis for GFAP expression in control animals indeed shows an inflammatory response along the 
injection tract at PID8. The occurrence of seizures in the first days after electrode implantation and 
their absence at later time points in control rats injected with saline in brain parenchyma is fully in 
line with an earlier study performed by our lab [28]. Similar acute seizures post-surgery in sham-
operated experimental controls have also been reported by Andrade et al. [29]. 
In GB rats, we found no clear correlation between number of seizures/day and time post-
inoculation, arguing against a tumor-related mass effect as the sole cause of seizures. One other study 
by Köhling et al. investigated epileptic activity in a GB rat model [13]. All transplanted rats (n = 4) 
showed short epileptiform discharges on EEG lasting several seconds, but in contrast to our 
observations, no epileptic seizures with behavioral abnormalities (judged on the basis of actograms 
and by visual inspection). Possible explanations for the lack of seizures in their model could be 
different rat strain (Wistar vs. Fischer), transplantation site (somatosensory vs. entorhinal cortex), and 
cell type (C6 cells vs. F98 cells). Indeed, C6 cells show circumscribed growth patterns, whereas F98 
cells are infiltrative [30]. Apart from tumor type (seizures are more common in LGG than in HGG), 
tumor location also influences the risk for epilepsy [8]. The incidence of epilepsy is higher for cortical 
than for non-cortical tumors, regardless of the involved lobe [9]. Entorhinal, piriform, and perirhinal 
cortex are highly interconnected with each other and with other limbic structures, and are, therefore, 
particularly prone to the genesis and propagation of ictal discharges [31]. Tumors involving 
mesiotemporal and insular (paralimbic) structures frequently result in medication-resistant epilepsy 
[9]. 
Mouse models for GB-related epilepsy are described in two studies by Buckingham et al. In the 
first study, SCID mice were either implanted with human GBM12/GBM22 xenografts (2.5 × 105 
cells/10 µL) or U251GFP human glioma cell line (5 × 105 cells/10 µL) in the left hemisphere. Very short 
epileptiform EEG events were seen in 37% of the mice, mostly associated with a subtle behavioral 
phenotype [14]. In the second study by Buckingham et al., GBM22 xenografts (1–1.5 × 105 cells) were 
implanted into one or both hemispheres. Seizures were detected in 80% of the mice [32]. Both 
methodologies have not led to a standardized mouse model protocol for GB-related epilepsy as there 
is no clear description of the exact injection site and electrode positions, different xenografts were 
used, and a high variability in seizure occurrence (37% vs. 80%) and seizure duration (0.5 s vs. 26 s) 
was reported in both studies. In another study, rat-derived glioma C6 cells (1 × 105 cells/5 µL) were 
inoculated into the right motor cortex of adult nude mice. Video-EEG was recorded 24/7 for 3 weeks 
and spontaneous seizures were measured in glioma-inoculated mice with an increase in seizure 
duration over time, whereas no seizures were measured in sham-implanted mice. However, the main 
focus of that study was not to establish an in vivo model for glioma-related epilepsy, but to 
investigate a role for glioma-induced alterations in KCC2 in the peritumoral region in tumor-
associated epilepsy and therefore, no detailed characterization of seizures was given [33]. 
Previously mentioned models were not designed to study the evolution of GB over time in 
relation to the occurrence of epilepsy and certainly not with personalized video-EEG monitoring. 
Therefore, to our knowledge, we are the first to describe progression and histopathological properties 
along with the occurrence of seizures and characteristics of these seizures in the syngeneic 
Fischer/F98 rat model of GB. 
This study had some limitations. First, a limited number of animals—seven GB rats and two 
control rats—were monitored with video-EEG. Despite this limitation, we did find a clear difference 
between groups in the occurrence of seizures with all GB rats, but none of the SHAM rats, displaying 
seizures in the later stages of video-EEG monitoring. Therefore, the occurrence of glioma-related 
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seizures in this model is consistent. Second, we injected only one type of glioma cell. To rule out that 
observed seizures are not cell line-specific, the results need to be confirmed in a model using another 
glioma cell line. Third, because we did not use MRI-compatible electrodes, it was not possible to 
combine MRI with video-EEG monitoring, which will be needed to directly link tumor characteristics 
(e.g., size, spread, edema) to tumor-related seizures. Fourth, this study showed reactive gliosis 
around the GB, but inflammatory responses were not addressed in detail. More extensive tissue 
analysis for markers of reactive microglia (e.g., Iba-1), axonal injury (e.g., NFL), and T-lymphocytes 
(e.g., CD45) should be performed to further characterize the inflammatory response. A multimodal 
approach combining video-EEG, MRI, and tissue analysis in this model will make it straightforward 
to screen treatments for both tumor growth and tumor-related seizures. 
4. Materials and Methods 
4.1. F98 Cells 
F98 (ATTC) rat GB cells were cultured as monolayers in Dulbecco’s Modified Eagle Medium 
(DMEM), supplemented with 10% fetal calf serum (FCS), 1% penicillin–streptomycin, 1% L-
glutamine, and 0.1% fungizone (all products for cell culture were purchased from Invitrogen® 
(Merelbeke, Belgium)) and placed in an incubator at 37 °C and 5% CO2. 
4.2. Animals 
Nineteen male F344/IcoCrl rats (Charles River®) with ages of 9–10 weeks and mean body weight 
of 245 ± 22 g were used. The study was approved by the animal ethics committee of the Faculty of 
Medicine and Health Sciences of Ghent University (ECD 17/111). All animals were kept and handled 
according to European guidelines (Directive 2010/63/EU) and housed under environmentally 
controlled conditions: 12 h light/dark cycle, temperature between 21 and 24 °C, and humidity 
between 55% and 65%. Food and water were provided ad libitum. 
4.3. Inoculation 
All animals were anesthetized with a mixture of medical oxygen and isoflurane (induction: 5%; 
maintenance: 2%) and immobilized in a stereotaxic frame. Body temperature was maintained at 37 
°C by a thermoregulated heating pad. The glioma cell suspension was stereotactically injected in the 
right entorhinal cortex (anterioposterial (AP): −8.0 mm and mediolateral (ML): +4.5 mm relative to 
bregma, dorsoventral (DV): −4.1mm relative to dura) using an insulin syringe (BD 0.5 mL Insulin 
Syringe Microfine 0.33 mm (29G) × 12.7 mm) mounted on a pump for automatic injection (Stoelting 
Quintessential Stereotaxic Injector, Stoelting Co., Wood Dale, IL, USA). In 15/19 animals (GB1–15), 
20,000 F98 cells in 5 µL phosphate-buffered saline (PBS) were injected over a period of 10 min. In four 
control animals (C1–4), 5 µL of PBS was injected. Of these control rats, two rats (C1–2) were used for 
video-EEG monitoring and two for RNAscope analysis preceded by MRI (Table 1). The syringe was 
kept in place for five minutes post-inoculation and then, slowly removed. The skin was sutured, and 
meloxicam was administered subcutaneously (1 mg/kg, 2 mg/mL) to manage pain due to surgery. In 
the remainder of this manuscript, we refer to the inoculation day as post-inoculation day 0 (PID 0). 
4.4. Brain Imaging Using Micro-MRI Confirmation and Follow-Up of Tumor Growth 
In vivo 7-tesla micro-MRI (PharmaScan 70/16, Bruker BioSpin, Ettlingen, Germany) was used to 
visualize brain lesions following inoculation to evaluate tumor growth (Table 1, M). Time points of 
MRI differed in subsets of rats. In the first group (GB1–5), MRI scans were performed on post-
inoculation day (PID) 3. As no tumors could be visualized yet, MRI was repeated on PID10 to confirm 
tumor growth prior to electrode implantation on PID11 or 12. Since tumors were extensive on PID10, 
a second group of rats (GB6–9) were scanned on PID6 and implanted with electrodes on PID7 or 8, 
which allowed the initiation of video-EEG monitoring earlier. A third group of rats (GB10–12 and 
C3–4) were scanned on PID8 before perfusion on day 9 for RNAscope analysis (see below). In a fourth 
Int. J. Mol. Sci. 2020, 21, 6999 13 of 19 
 
group of rats (GB13–15), MRI was performed on PID14 and 19 to visualize tumors at later stages, 
which is not feasible once electrodes are implanted for video-EEG monitoring. 
Animals were anesthetized with a mixture of oxygen and isoflurane (induction: 5%; 
maintenance: 2%) and placed in the scanner, where the isoflurane-oxygen mixture was administered 
through a nose cone fixed onto the animal holder. A heating pad using a warm water circuit to 
maintain body temperature at 37 °C was placed underneath the animal. A volume coil (Rapid 
Biomedical, Rimpar, Germany) was placed around the head. Respiratory rate was monitored during 
the entire protocol. A localizer scan was performed, followed by a T2-weighted spin-echo scan 
(TR/TE 3661/37.1 ms, 109 µm isotropic in-plane resolution, slice thickness 0.6 mm, 4 averages, TA 
9′45″). 
MRI tumor volumes were defined as the extent of a hyperintense signal on MRI reflecting the 
tumor itself, the infiltrative border, and brain edema. These volumes were calculated from T2-
weighted images using ImageJ (National Institutes of Health, Bethesda, MD, USA). On each MRI slice 
with visible lesions, the hyperintense signal around the inoculation site in the right-sided temporal 
lobe was marked and the surface area was determined. MRI tumor volumes per rat brain were 
calculated by summating the surface areas and by multiplying the mean surface area by 0.6 mm (0.6 
mm slice thickness). 
Moreover, qualitative aspects of MRI images were examined as well, such as deformation of the 
brain and MRI tumor characteristics over time. 
4.5. Electrode Implantation for EEG Recording 
One or two days after confirmation of tumor presence with MRI, a subset of animals (8/15 GB 
rats, GB2–9) were anesthetized with a mixture of medical oxygen (rate: 1 L/min) and isoflurane 
(induction: 5%; maintenance: 2%) and their heads were fixated in a stereotaxic frame. For recording 
of epidural EEG, a scalp electrode was placed over the right parietal cortex near the tumor border. 
Epidural scalp electrodes were custom-made and consisted of a stainless-steel micro screw (0.8 mm 
diameter, Plastics One, Roanoke, VA, USA) soldered to an insulated copper wire. At the connector 
side, electrode wires were sandwiched between two Winslow connector pins (267–7400, RS 
components, Colby, UK). Two additional scalp electrodes (serving as ground and spare ground) and 
two anchor screws were implanted in the os frontale, one anchor screw in the os parietale, and three 
anchor screws in the os occipitale. Two small craniotomies were made for placement of bipolar depth 
electrodes (tips 0.9 mm apart) in left and right hippocampus (AP: −5.0 mm; ML: +/−3.5 mm relative 
to bregma). Via a small incision in the dura, electrodes were inserted in the brain using audio control 
(i.e., unit activity). When the deepest contact point reached the dentate gyrus (−3.2 ± 0.6 mm below 
dura), electrodes were fixed to the skull and neighboring anchor screws using UV cement (Filtek 
Supreme XTE Plus Flowable 2 × 2 gr, 3M, Diegem, Belgium). At the end of the surgery, the connector 
pins of all electrodes were assembled in a connector block (female side exposed) and secured to the 
skull using metabond (Super-Bond C&B, Sunmedical, Shiga, Japan) and dental cement (Simplex 
Rapid fluid/powder, Kemdent, Swindon, UK). Meloxicam (1 mg/kg, 2 mg/mL) was administered 
subcutaneously after surgery. In two control rats, electrodes were implanted 5 days after injection of 
PBS (Table 1, E). 
4.6. Continuous Video-EEG Monitoring 
Continuous video-EEG monitoring was performed as described previously by Germonpré et al. 
and is explained here in short [28]. After electrode implantation surgery, animals were housed in 
neurophysiology cages (Plexiglas 29 × 29 × 45 cm) where they were connected to a video-EEG 
monitoring setup. 
This setup consisted of a headstage carrying a 4-channel unity gain amplifier, a tether, and a 12-
channel commutator (Plastics One, Roanoke, VA, USA), allowing the animals to move freely. EEG 
signals were high-pass filtered at 0.15 Hz and amplified 512×. A NiDAQ card (USB-6259, National 
Instruments device, Austin, TX, USA) with 32 analog input channels (8 rats, 4 channels/rat) was used 
to digitize the EEG at a sampling rate of 2 kHz (16-bit resolution, +/− 10 V input range). 
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The behavior of each animal was individually monitored with a camera (Raspberry Pi 3) in front 
of the cage. Both EEG and video were recorded continuously after electrode implantation until 
euthanasia. Rear and side walls were covered with mirror foil, making it possible to visualize the 
animal from all possible angles. Infrared lights allowed for visualization of the animal in the dark. 
A MATLAB-based application was used to control the acquisition and storage of the EEG and 
video files. 
Electrographic seizures were defined as rhythmic patterns of EEG spikes with evolving 
complexity and an amplitude exceeding at least three times the baseline amplitude and lasting more 
than 10 s. The start and end of seizures were determined using a subjective “by eye” evaluation of 
the EEG signal recorded from the ipsilateral dentate gyrus (Figure 2, DGi). If a seizure was detected 
on the EEG, corresponding videos were used to detect any clinical symptoms or to exclude non-
epileptic activity (scratching, drinking, etc.). A modified Racine Behavioral Scale [34] was used to 
score behavioral changes during seizures: Stage 1: mouth and facial movements (incl. wet dog 
shakes), stage 2: head nodding, stage 3: unilateral forelimb clonus, stage 4: bilateral forelimb clonus 
and rearing, and stage 5: clonus of all limbs and falling. Based on this Racine scale, seizures were 
classified as non-convulsive (no clear motor component; stage 1–2) and convulsive (clear motor 
component; stage 3–5) seizures. The number of seizures per rat per stage was evaluated, as well as 
the number of GB/control rats with seizures per day and the number of (non-convulsive) seizures in 
GB/control rats with seizures per day. The duration of seizures, occurrence of seizures during 
light/dark phase, and median severity of seizures were also investigated. 
4.7. Histology 
All seven GB rats and both control rats that were monitored with video-EEG were euthanized 
at day 21 with an overdose of sodium pentobarbital (200 mg/kg, Vétoquinol S.A./N.V., Aartselaar, 
Belgium) which was administered intraperitoneally under isoflurane anesthesia. GB2–5 were 
transcardially perfused with PBS followed by 4% paraformaldehyde (PFA) (Table 1, H(●)). We found 
that PFA-based fixation of brain tissue, followed by sucrose-based cryoprotection and frozen section 
procedure, was unsuitable for histological analysis of tumor size as well as for immunohistochemical 
analysis in this model. Making free-floating sections with a thickness of 40 µm of these PFA-perfused 
brains resulted in tumor tissue detachment from the remaining brain tissue that led to teared slices 
without tumor tissue. This problem was solved by snap freezing fresh brain tissue and making 5-µm-
thick frozen sections that were immediately mounted. Therefore, GB6–9 and C1–2 were transcardially 
perfused with saline at room temperature followed by ice cold PBS (Table 1, H). Brains were isolated 
and immediately frozen in liquid nitrogen. 
Coronal sections (5 µm) were prepared using a cryostat (Leica, Wetzlar, Germany) from these 
latter six brains. Each 100th slice was mounted directly on a glass slide and a cresyl violet staining 
was performed. Some additional slices for immunohistochemical analysis were also mounted and 
stored in a −80 °C freezer (see Section 4.8. Immunohistochemistry). Tumor volumes on PID21 were 
calculated based on digitized histological slices using ImageJ (National Institutes of Health, Bethesda, 
MD, USA). On each slice, the tumor border (i.e., border aligning darker stained areas and significant 
infiltration zones) was marked and surface area was determined. Histological tumor volumes per rat 
brain were calculated by summating tumor surface areas determined on all tumor containing slices 
and multiplying this average surface area by 0.5 mm (5 µm slice thickness + 495 µm interslice 
thickness). Furthermore, histological characteristics such as necrosis, cell morphology, and 
infiltration were investigated on these digitized slices. 
4.8. Immunohistochemistry 
Immunohistochemical stainings for the astrocytic markers glial fibrillary acidic protein (GFAP) 
and vimentin, and for the cell proliferation marker Ki-67 were performed. Briefly, 5 µm-mounted 
slices were first treated with 0.5% and 1% H2O2 in PBS for 30 and 60 min, respectively, to block 
endogenous peroxidase activity. Secondly, sections were incubated for 45 min with a blocking 
solution containing PBS, 0.2% Triton X-100 and 0.4% Fish Skin Gelatin. Next, primary antibodies were 
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applied for 1 h at room temperature at the following dilutions: rabbit anti-GFAP (1:1000; DAKO, 
Heverlee, Belgium), mouse anti-vimentin (1:250; DAKO, Heverlee, Belgium), and anti-rabbit Ki-67 
(1:100; Fisher Scientific, Merelbeke, Belgium). After extensive washing, the sections were incubated 
for 1 h with goat anti-rabbit-Alexa fluor 594 (1:1000; DAKO, Heverlee, Belgium) and/or goat anti-
mouse-Alexa fluor 488 (1:1000; DAKO, Heverlee, Belgium) secondary antibodies. After thorough 
rinsing, DAPI (1 µg/mL) was applied for 1 min for nuclear staining. A droplet of Vectashield 
Mounting Medium Fluorescence was applied to the slices and slices were coverslipped. For Ki-67 
staining, five random high-power fields (40×) in tumor tissue and five in non-tumor tissue were 
evaluated by counting positive and negative nuclei. The estimated number of positive Ki-67+ nuclei 
was divided by the estimated number of counted nuclei (DAPI+) to obtain an estimated proliferation 
index. GFAP and vimentin expression in tumor and non-tumor tissue was also estimated by counting 
positive and negative nuclei in these high-power fields. 
4.9. RNA Scope Assay 
RNAscope was used in order to visualize GFAP mRNA in GB-containing brain slices. This is a 
novel RNA in situ hybridization (ISH) technology with a unique probe design strategy that allows 
simultaneous signal amplification and background suppression to achieve single-molecule 
visualization with the preservation of tissue morphology [35]. GB10–12 and C3–4 were sacrificed 9 
days post-inoculation and their brains were collected in RNAse-free conditions, followed by snap 
freezing in liquid nitrogen (Table 1, R). Brains were then sliced to provide 12-µm-thick coronal 
sections using a microtome and kept at −80 °C until further processing. 
GFAP mRNA was targeted with RNAscope® Probe-Rn-Gfap-C2 reagent (ACDbio, Newark, 
CA), a mixture of 20 probes targeting the region from 1539 to 2534bp of the rat GFAP mRNA sequence 
(accession number: NM_017009.2). 
Sections were fixed for 1 h in 4% PFA at 4 °C directly out of the −80 °C freezer and rinsed three 
times in PBS before dehydration. The dehydration procedure was done at room temperature. Sections 
were incubated in 50% EtOH, 70% EtOH, and 100% EtOH for 5 min each and in 100% EtOH for 10 
min. The sections were air-dried for 5 min before to draw a barrier around it with a hydrophobic 
barrier pen. The barrier was left to dry for 1–2 min and RNAscope protease IV (ACDbio, Newark, 
CA, USA) diluted at 1/15 in PBS was added to cover the sections for 30 min at room temperature. The 
protease was rinsed two times for 2 min in PBS and the GFAP probe was added to cover the sections. 
The sections were inserted in the HybEZ Oven (ACDbio, Newark, CA, USA) for 2 h at 40 °C in the 
HybEZ Humidity control tray (ACDbio, Newark, CA, USA) with a wet HybEZ Humidifying paper 
(ACDbio, Newark, CA, USA). The 50× RNAscope® Probe-Rn-Gfap-C2 was prepared at 1× with probe 
diluent and warmed for 10 min at 40 °C before use. After probe hybridization, the samples were 
rinsed two times for 2 min in wash buffer (ACDbio, Newark, CA, USA) and kept overnight in Saline 
Sodium Citrate (0.75 M NaCl in 75 mM sodium citrate (pH 7.0)) buffer. 
For the amplification and detection steps, reagents were brought to room temperature before the 
start. RNAscope Multiplex FL V2 AMP1 (ACDbio, Newark, CA, USA), the preamplifier, hybridizing 
only pairs of probes to limit the risk of unspecific binding, was added to the section for 30 min at 40 
°C. Then, RNAscope Multiplex FL V2 AMP2 (ACDbio, Newark, CA, USA), the amplifier, hybridizing 
the preamplifier to provide a support for the label probe and RNAscope Multiplex FL V2 AMP3 
(ACDbio, Newark, CA, USA) serving as linker for the preamplifier and amplifier, were added for 30 
and 15 min respectively at 40 °C. 
For the detection step, we used RNAscope Multiplex FL V2 HRP-C2 (ACDbio, Newark, CA, 
USA), binding to the amplifier of the C2 channel, and added it for 15 min at 40 °C. The TSA Plus 
Cyanine 3 System (PerkinElmer, Waltham, MA, USA) revealing the C2 channel and RNAscope 
Multiplex FL V2 HRP blocker (ACDbio, Newark, CA, USA) blocking HRP from further reaction with 
the TSA system were added for 30 and 15 min, respectively, at 40 °C. 
For the amplification and detection steps, two rinses for 2 min with wash buffer at room 
temperature after each step were performed. 
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Finally, the sections were stained for 45 s with RNAscope Multiplex FL V2 DAPI (ACDbio, 
Newark, CA, USA) and mounted with antifade mounting medium. 
Images were acquired with the Axio Scan.Z1 (Zeiss, Oberkochen, Germany) with 40× objective 
and analyzed with Zen microscope software (Zeiss, Oberkochen, Germany). 
Per GB rat, one slice near the inoculation site was selected and the area of dense tumor cells 
(marked by strong DAPI signal) and the composite area of dense tumor cells + astrogliotic rim 
surrounding the dense tumor cells (marked by high levels of GFAP mRNA) were determined. These 
areas were compared with the area of hyperintense MRI signal at the inoculation site detected in the 
corresponding animals on PID8. For comparison, the areas were normalized by dividing them by the 
total brain area on the selected RNAscope/MRI slices, respectively. 
4.10. Statistical Analysis 
All statistical analyses were performed in SPSS version 26 (Chicago, IL, USA) with the level of 
statistical significance set at 0.05. Unless otherwise stated, data are expressed as medians and range. 
Non-parametric tests were used due to the low number of animals. Mann–Whitney U Test was used 
to compare the duration of non-convulsive and convulsive seizures in GB rats as well as to compare 
MRI tumor volumes and histological tumor volumes. Wilcoxon Signed Rank Test was used to 
compare the occurrence of seizures during light vs. dark phase and to compare the number of 
convulsive vs. non-convulsive seizures in GB rats. 
5. Conclusions 
Until today, no standardized in vivo rodent model for GB-related epilepsy exists. The 
development of this rat model for GB-related epilepsy allows for the monitoring of seizures in a 
reproducible manner and the characterization of the tumor microenvironment in epileptic rats. This 
will allow screening for new therapies against tumor growth and associated epileptic seizures. Since 
survival is only 21 days in this model, we suggest initiating treatments as early as possible. 
Furthermore, to investigate treatments against GB-associated seizures, sufficient animals need to be 
included in the experiments as a high interindividual variability in the number and occurrence of 
seizures was seen. 
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Abbreviations 
GB Glioblastoma 
MRI Magnetic Resonance Imaging 
EEG Electroencephalography 
mRNA Messenger-Ribonucleic Acid 
WHO World Health Organization 
LGG Low-grade glioma 
HGG High-grade glioma 
DRE Drug-resistant epilepsy 
MEG Magnetoencephalography 
PID Post-inoculation day 
M MRI scan 
E EEG electrode implantation 
R RNAscope analysis 
H Histological analysis 
H(●) No histological analysis due to problems with histological processing 
RWS Fraction of rats with seizures per day 
NCS Total number of non-convulsive seizures 
CS Total number of convulsive seizures 
DGi Ipsilateral dentate gyrus 
CA1i Ipsilateral CA1 
DGc Contralateral dentate gyrus 
Cp Parietal cortex 
GFAP Glial Fibrillary Acidic Protein 
SD Standard deviation 
DAPI 4′,6-diamidino-2-phenylindole 
T Tumor tissue 
NT Non-tumor tissue 
I Infiltrative spot 
N Necrotic spot 
SEM Standard error of the mean 
SCID Severe combined immunodeficiency 
KCC2 Potassium chloride cotransporter 2 
ATTC American Type Culture Collection 
DMEM Dulbecco’s Modified Eagle Medium 
FCS Fetal calf serum 
ECD “Ethische Commissie Dierproeven” 
AP Anterioposterial 
ML Mediolateral 
DV Dorsoventral 
PBS Phosphate-buffered saline 
C Control 
TR Repetition time 
TE Echo time 
TA Acquisition time 
NiDAQ National instruments Data Acquisition 
PFA Paraformaldehyde 
ISH In situ hybridization 
EtOH Ethanol 
NaCl Sodium chloride 
HRP Horseradish peroxidase 
TSA Tyramide signal amplification 
SPSS Statistical Package for the Social Sciences 
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